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A Toxic Conformer of Aβ42 
with a Turn at 22–23 is a Novel 
Therapeutic Target for Alzheimer’s 
Disease
Naotaka Izuo  1, Chihiro Kasahara1, Kazuma Murakami2, Toshiaki Kume3, Masahiro Maeda4, 
Kazuhiro Irie  2, Koutaro Yokote5 & Takahiko Shimizu  1
Immunotherapy targeting Aβ42 is drawing attention as a possible therapeutic approach for Alzheimer’s 
disease (AD). Considering the significance of reported oligomerized Aβ42 species, selective targeting 
of the oligomer will increase the therapeutic efficacy. However, what kinds of oligomers are suitable 
targets for immunotherapy remains unclear. We previously identified a toxic conformer of Aβ42, 
which has a turn structure at 22–23 (“toxic turn”), among Aβ42 conformations. This toxic conformer 
of Aβ42 has been reported to show rapid oligomerization and to exhibit strong neurotoxicity and 
synaptotoxicity. We recently developed a monoclonal antibody against the toxic conformer (24B3), 
which demonstrated the increase of the toxic conformer in the cerebrospinal fluid of AD patients, 
indicating its accumulation in AD patients’ brains. In this study, we evaluated the therapeutic efficacy 
of 24B3 targeting the toxic conformer in AD model mice. The intraperitoneal administration of 24B3 
for 3 months improved cognitive impairment and reduced the toxic conformer levels. Notably, 
this treatment did not reduce the number of senile plaques. Furthermore, the single intravenous 
administration of 24B3 suppressed the memory deficit in AD mice. These results suggest that the toxic 
conformer of Aβ42 with a turn at 22–23 represents one of the promising therapeutic targets.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease in which cognitive impairment is one of the 
main symptoms. The pathological hallmarks of AD include the deposition of senile plaques and neurofibrillary 
tangles, each of which is mainly composed of amyloid β (Aβ)1 and excessively phosphorylated tau2. The 40-mer 
and the 42-mer Aβ (Aβ40 and Aβ42, respectively) are produced from their precursor protein (APP) with two-step 
endoproteolysis by β-secretase and γ-secretase, which includes presenilin 1 or 2 (PS1 or PS2, respectively) as an 
activity center3. The resultant Aβ assembles and forms oligomers to induce neurotoxicity and synaptotoxicity1,4. 
The importance of Aβ42 in the pathogenesis of AD has been supported by numerous studies based on genetics 
and biochemistry5–7. In a recently reported clinical trial, immunotherapy with the aim of Aβ clearance achieved 
certain results in AD patients; a decrease in senile plaque deposition and the suppression of cognitive impair-
ment8. These outcomes confirmed that Aβ is a therapeutic target for AD8,9. However, some problematic adverse 
effects, including edema and micro-hemorrhage, were observed in the clinical trials8; thus, there is a need to 
modify this treatment approach.
Aβ, a kind of intrinsically disordered proteins, is known to mainly adopt a random coil or α-helix conforma-
tion10, and the transition to β-sheet leads to its aggregation and oligomerization in a test tube11–13, which sug-
gests the conformational diversity of Aβ in live animals. In addition, Aβ has various physiological functions and 
pathological functions. Physiologically, Aβ has been reported to exhibit neuroprotective14 and neurotrophic15,16 
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effects, and to be involved in the fine-tuning of neurotransmission17, the regulation of glucose homeostasis18,19 
and immunomodulation20–22. Given such multiple physiological activities, the non-specific targeting of Aβ has 
the potential to cause adverse effects. This is assumed to be one of the causes of the clinical failure of Aβ-targeting 
immunotherapy for AD23–26. However, among the various conformations of Aβ, the conformations that are asso-
ciated with the pathogenesis of AD remains to be elucidated.
We have been investigating the conformation of Aβ42 that is crucial for the pathogenesis of AD. Through 
a long series of biophysical and biochemical analyses, we identified a “toxic conformer” of Aβ42, which has a 
turn structure at positions 22–23 (“toxic turn”)27–33 and which induces quick β-sheet formation29,32,34, potent 
neurotoxicity29,32,34–36, and strong synaptotoxicity35 (Fig. 1a). Recently, three independent research groups con-
firmed that Aβ42 makes a turn at positions 22–2337–39, and Lyubchenko’s group also showed the significance of 
the sequence H14-D23, which mediates aggregation in the nanomolar order40–42. The formation of the turn at 
positions 22–23 brings Tyr10 and Met35 closer, thereby accelerating radical production31 (Fig. 1a), which con-
tributes to the formation of the hydrophobic core in the C-terminus of Aβ4229,30, resulting in stable assembly as 
low-molecular-weight oligomers32,43 (Fig. 1a). For further investigation, we developed a specific antibody for 
the toxic conformer of Aβ4243,44. We obtained two representative antibodies (11A1 and 24B3) by the immuni-
zation of E22P-Aβ10–35, a minimal Aβ fragment to induce neurotoxicity, to mice and by the screening with the 
criteria of the positivity to the turn-forming Aβ42 mutants and the negativity to the turn-breaking mutants43,44 
Figure 1. The protective effect of 24B3 on the neurotoxicity induced by Aβ42. (a) A schematic illustration of 
the structure of the toxic conformer of Aβ42, which possesses a turn structure at 22–23 (“toxic turn”). The toxic 
turn formation draws Y10 and M35 closer to accelerate radical transition31, which contributes to the formation 
of the hydrophobic core in the C-terminus of Aβ4229,30, resulting in the stable assembly as low-molecular-weight 
oligomers32,43. 24B3 was developed as a conformation-specific antibody against the toxic turn structure. The 
epitopes of the conventional anti-Aβ antibodies, 6E10 and 82E1, are E3-S8 and N-terminus, respectively. (b and 
c) The antibodies are mixed with Wt-Aβ42 (b) or E22P-Aβ42 (c) before the treatment, and the mixtures were 
applied to primary cortical neurons. Wt-Aβ42 and E22P-Aβ42 were applied at a concentration of 1 µM for 96 h. 
Antibodies were applied at a concentration of 0.1 mg/ml (approximately 0.685 µM). ***p < 0.001 vs vehicle 
(Veh). #p < 0.05, ###p < 0.001.
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(Fig. 1a). 11A1 detected the intracellular accumulation of the toxic conformer of Aβ42 in neurons derived from 
the iPSCs of AD patients45 and in AD model mice46. 24B3, which shows higher specificity to the toxic conformer 
than 11A143, captured the toxic conformer in the cerebrospinal fluid (CSF) of AD patients43. These observations 
indicate that the toxic conformer exists in the brain of AD patients. Moreover, it is noteworthy that the ratio of the 
toxic conformer to total Aβ42 increased in the CSF of AD patients43, suggesting the potential application of 24B3 
in the diagnosis of AD. These results indicate the possibility that the toxic conformer of Aβ42 is a therapeutic tar-
get in AD. In this study, we investigated the effects of the administration of 24B3 to AD mice in order to evaluate 
this hypothesis.
Results
Neutralization of the toxic conformer with 24B3 suppressed the neurotoxicity induced by syn-
thetic Aβ42. Previous studies have reported that synthetic wild-type (Wt)-Aβ42 spontaneously forms the 
toxic conformer, which is detected by 24B3 (Fig. 1a)43. We investigated the effects of 24B3 on the neurotoxic-
ity induced by Wt-Aβ42 (Fig. 1b) and E22P-Aβ42 (Fig. 1c), which mimics the toxic conformer, on rat primary 
cortical cultures. E22P-Aβ42 was previously reported to draw Y10 and M35 closer and thereby induce radical 
transfer, leading to the stable formation of the toxic conformer of Aβ4231. Wt-Aβ42 and E22P-Aβ42 (1 µM, 96 h) 
induced significant neurotoxicity in MTT assay (Fig. 1b and c). Control-IgG showed no effects on Aβ42-induced 
neurotoxicity, while 24B3 almost completely suppressed the Aβ42-induced neurotoxicity (Fig. 1b and c). Similar 
protective effects against Aβ42 were obtained in the previous study in which 24B3 was applied to neuroblastoma 
SH-SY5Y cells43. On the other hand, another anti-Aβ antibody 6E10, the epitope of which is located at positions 
E3 to S8 (Fig. 1a), did not inhibit Aβ42-induced neurotoxicity; this result is supported by the report from Glabe 
et al.47. Moreover, 82E1, which reacts with the N-terminus of Aβ (Fig. 1a), did not show any protective effects 
against Aβ42-induced neurotoxicity in SH-SY5Y cultures43. These results suggest the significance of the toxic 
turn structure at 22–23 in the induction of neurotoxicity of Aβ42 and the effectiveness of targeting such a turn 
structure for suppressing neurotoxicity in vitro.
The toxic conformer of Aβ42 is detected in the soluble fraction of the brain of AD model mice 
by 24B3. We recently constructed an ELISA system, with 82E1 for capturing and 24B3 for detecting, to ena-
ble us to detect and quantify the toxic conformer in the CSF from AD patients43. We also attempted to detect 
the toxic conformer in AD model mice. In this trial, we selected Tg2576, which harbors human APP with the 
Swedish mutation, with overexpression of human PS2 carrying the Volga German Kindred mutation (N141I)48, 
which increases the ratio of Aβ42 to Aβ40 to accumulate severely amyloid plaques in these double transgenic 
mice (PS2Tg2576)49. The toxic conformer in the brain soluble fraction prepared from PS2Tg2576 was positively 
detected by using our ELISA (Fig. 2a)49. The Aβ42 (Fig. 2b) and Aβ40 (Fig. 2c) contents in this fraction were con-
sistent with those previously reported49. To investigate the presence of the toxic conformer in the senile plaques, 
we performed immunohistochemical staining of brain sections from AD model mice by 24B3. The numeric value 
of the group of Wt mice is probably a nonspecific signal in ELISA. 82E1 (0.5 µg/ml) staining clearly detected the 
deposition of senile plaques (Fig. 2d and f), while 24B3 (20 µg/ml) showed no staining (Fig. 2e and g). These 
results suggest that the toxic conformer was present in the soluble fraction, rather than in the senile plaques in 
AD mice. In our related study, we also found another stable conformer of Aβ42 with a turn structure at 25–26 that 
might be a physiological conformation and named it “non-toxic conformer”29,32. This turn structure at 25–26 was 
also observed in Aβ40 fibrils50. We confirmed the immunoselectivity of 24B3 between the toxic and non-toxic 
conformers, by immunoprecipitation (IP) without denaturing condition (Supplementary Fig. 1). In this exper-
iment, 24B3 exhibited direct binding to monomer and oligomer of E22P-Aβ42, but not to G25P-Aβ42, a mimic 
of the non-toxic conformer.
The chronic administration of 24B3 ameliorated behavioral abnormalities in PS2Tg2576. Since 
the presence of the toxic conformer in the brain of the AD model mice was clarified, we investigated whether 
the passive immunization of 24B3 could ameliorate behavioral abnormalities. PS2Tg2576 show senile plaque 
deposition from 2–3 months of age and cognitive impairment from 4–5 months of age (Fig. 3a)49. To investigate 
the effects of the chronic administration of 24B3, the mice underwent passive immunization from 3 months 
to 6 months of age and received a behavioral test at 6 months of age, and then were sacrificed. Antibodies 
(control-IgG, 82E1 and 24B3) were intraperitoneally administrated to PS2Tg2576 at the dose of 10 mg/kg once 
a week. The behavioral abnormalities of the mice were evaluated by elevated plus maze (EPM) test reflecting 
the spatial cognition of height (Fig. 3b) and nest construction test estimating executive function (Fig. 3c and 
Supplementary Fig. 2). In the EPM test, the duration that PS2Tg2576 administered control-IgG spent in the open 
arm was significantly longer than in Wt mice, suggesting the impairment of spatial cognition (Fig. 3b). The mice 
administered 24B3 stayed in the open arm for a normal length of time like Wt mice, while 82E1 did not reduce 
the time in the open arm (Fig. 3b). In the nest construction test, PS2Tg2576 administered control-IgG were 
incapable of nest building, indicating the disturbance of the executive function (Fig. 3c). Similarly to the EPM 
test, the administration of 24B3 restored the ability to construct a nest; the mice administered 82E1 were poor at 
nest building (Fig. 3c). These data suggest that the chronic administration of 24B3, but not 82E1, suppressed the 
impairment of spatial cognition and executive function in AD mice.
The chronic administration of 24B3 significantly reduced the levels of the toxic conformer of 
Aβ42 without affecting the senile plaque pathology. To investigate the effects of the chronic immu-
nization on Aβ pathology, we performed immunohistochemical and biochemical analyses. Brain sections from 
PS2Tg2576 with passive immunization were stained by 82E1. Passive immunization with 82E1 reduced the num-
ber of the senile plaques in PS2Tg2576 compared with the mice administered IgG (Fig. 4a,b and d). Interestingly, 
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immunization with 24B3 did not reduce the number of plaques (Fig. 4a,c and d). There were no differences in 
the average size of the plaques among the three groups (Fig. 4e). Microglia play a role in clearing senile plaques 
by phagocytosis. Consistent with the effects of 24B3 on plaque pathology, 24B3 did not affect microglial acti-
vation (Supplementary Fig. 3). Next, we prepared soluble and insoluble brain fractions to measure the levels of 
Aβ. The levels of the toxic conformer in the soluble fraction were significantly reduced by the administration of 
24B3, but not of 82E1 (Fig. 5a). On the other hand, there were no significant differences in the levels of the total 
Aβ42 (Fig. 5b and d) or Aβ40 (Fig. 5c and e) in the soluble or insoluble fractions among the IgG-, 82E1- and 
24B3-treated groups. Taken together, the chronic administration of 24B3 ameliorated the cognitive deficits in 
PS2Tg2576 with the reduction in the levels of the toxic conformer of Aβ42, without affecting plaque pathology. 
In contrast, while 82E1 reduced the number of the senile plaques, it did not suppress the abnormal behaviors.
The single administration of 24B3 ameliorated the memory impairment of Tg2576. The exper-
iment with the chronic regimen exhibited a suppressive effect on cognitive impairment in the AD model mice 
in two kinds of behavioral tests, accompanied by a reduction in the amount of toxic conformer in the soluble 
fraction but not in the senile plaques. These results suggest that targeting the toxic conformer is sufficient to 
suppress the cognitive deficit in AD model mice. Thus, we next tried another regimen to investigate the effects 
of the acute administration of 24B3 in aged Tg2576, another AD model mice (Fig. 6a). The memory impairment 
Figure 2. 24B3 detects the toxic conformer of Aβ42 in the soluble fraction from the brain of AD model mice. 
(a–c) The levels of the toxic conformer of Aβ42 (a), total Aβ42 (b), and total Aβ40 (c) in the soluble fraction 
of the brain of PS2Tg2576 at 6 months of age. (d–g) Immunohistochemical staining of brain sections from 
PS2Tg2576 was performed with 82E1 (0.5 µg/ml) (d and f), and 24B3 (20 µg/ml) (e and g). The slices were 
exposed to formic acid for antigen activation. High magnification images of the area inside the red rectangles  
(d and e) are shown in f and g. **p < 0.01.
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was evaluated in novel object recognition (NOR) test (Supplementary Fig. 4). In trial 1, Wt and Tg2576 mice were 
treated with PBS. Wt mice exhibited a preference for a novel object, while Tg2576 did not (Fig. 6b), confirming 
that Tg2576 exhibited memory decline. In trial 2, Wt mice were treated with PBS, while Tg2576 mice were treated 
with IgG or 24B3. Tg2576 that were treated with IgG exhibited no preference, while Tg2576 treated with 24B3 
showed a preference for a novel object (Fig. 6c), suggesting that the single administration of 24B3 improved the 
memory impairment in AD mice. Surprisingly, a single dose of 24B3 did not reduce the levels of the toxic con-
former (Fig. 6d), as well as those of Aβ42 (Fig. 6e) or Aβ40 (Fig. 6f) in the soluble fraction. These results suggest 
that only capture of the toxic turn of Aβ42 is sufficient to improve the memory function. This result is consistent 
with the results of the in vitro neutralization experiment (Fig. 1).
Discussion
The toxic conformer of Aβ42 in PS2Tg2576 was not detected in senile plaques and was detected in the soluble 
fraction by ELISA with 24B3 (Fig. 2), indicating that the toxic conformer mainly exists in the soluble fraction 
in AD brains. These findings do not contradict with the clinical evidence showing that the toxic conformer is 
detected in the CSF from AD patients43. An Aβ42 mutant with a deletion at position 22, Osaka mutant, which 
is discovered as a familial mutation that is associated with Alzheimer’s-type dementia51, is suggested to prefer-
ably form the toxic conformer and soluble oligomer35; the patients and transgenic mice with this mutation do 
not accumulate senile plaques51,52. This evidence also supports our hypothesis that the toxic conformer mainly 
exists in a soluble oligomer. The chronic administration of 24B3 improved the executive dysfunction and spatial 
cognitive impairment of AD model mice (Fig. 3), and significantly reduced (by ~40%) the levels of the toxic 
Figure 3. The chronic administration of 24B3 ameliorated behavioral abnormalities in PS2Tg2576. (a) A 
protocol for the chronic administration of 24B3. PS2Tg2576 exhibits senile plaque accumulation from 2–3 
months of age, and cognitive impairment from 4–5 months of age. Control-IgG, 82E1 and 24B3 (10 mg/kg/
week) were intraperiosteally administered to PS2Tg2576 at from 3 months to 6 months of age. At 6 months 
of age, the behavioral tests were performed and the mice were sacrificed. Wt mice received PBS, which was 
administered at the same frequency as the antibodies. The numbers of mice in each group were as follows: 
Wt (n = 9), PS2Tg2576 + IgG (n = 7), PS2Tg2576 + 82E1 (n = 7), and PS2Tg2576 + 24B3 (n = 8). (b) The 
suppressive effect of 24B3 on behavioral abnormalities in elevated plus maze test. 24B3-treated PS2Tg2576 spent 
normal time in the open arm. (c) The suppressive effect of 24B3 on behavioral abnormality in nest construction 
test. The nest building ability of 24B3-treated PS2Tg2576 was restored. **p < 0.01, *p < 0.05.
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conformer in the soluble fraction (Fig. 5) without affecting the plaque pathology (Fig. 4). In contrast, the admin-
istration of 82E1 (the anti-N terminus of Aβ42) by the same protocol did not suppress abnormal behaviors, even 
though it reduced the number of plaques (Figs 3 and 4). These results did not contradict the results showing that 
the localization of the toxic conformer was limited to the soluble fraction, rather than the plaques (Fig. 2). Aβ 
oligomers are classified into two groups: those oriented to senile plaques (“on-pathway”), and those not oriented 
(“off-pathway”); the toxic oligomer derived from the toxic conformer might be an off-pathway oligomer53. These 
findings raise the important suggestion that the toxic conformer of Aβ42 in the soluble oligomer fraction, not in 
senile plaques, is a promising target to improve the cognitive impairment associated with AD, and that the thera-
peutic target should be the soluble oligomers with toxic conformation, not the plaques (Fig. 7).
So far, a series of anti-Aβ antibodies have been evaluated in the clinical trials and most of them failed to show 
their effectiveness because of the lack of potency or unignorable side effects23–26. The late intervention and inac-
curacy of the clinical diagnosis have been suggested as reasons for clinical failure. In addition to these points, it 
is necessary to re-evaluate the epitope of each antibody to ensure the efficacy of therapies. Despite the apparent 
reduction of the number of senile plaques, the administration of bapineuzumab, the epitope of which is the Aβ 
sequence of D1-R5, did not result in a clinically significant cognitive improvement23,26,54,55. These outcomes are 
similar to our results from 82E1 administration (Figs 3 and 4). This may be because most of the antibodies are 
occupied by the Aβ monomers rich in AD brains, and the remaining antibodies are unable to capture a sufficient 
volume of toxic Aβ oligomers, including the toxic conformer. In the EPM test, 82E1 resulted in a non-significant 
worsening trend in cognitive impairment. This may be derived from the removal of the monomeric Aβ42, which 
is reported to modulate the neuronal signal transmission. A number of antibodies against the N-terminus of 
Aβ42 are reported to suppress the behavioral abnormalities in AD model mice56. In this study, 82E1 reduced the 
number of senile plaques in PS2Tg2576 by only about half. Since this effect is not as strong as in other previously 
reported antibodies56, the failure of 82E1 to suppress the behavioral abnormalities does not contradict the find-
ings of previous studies56. Furthermore, solanezumab, which is a “sequence-specific” antibody to H13-K28, did 
not improve cognitive impairment in clinical trials24,25. It was reported that solanezumab is likely to capture mon-
omeric Aβ, thus this antibody probably has low affinity to the toxic turn of the toxic conformer. This may be one 
reason for the clinical failure. In our previous observations, 4G8, which binds to a specific “sequence” of L17-V24, 
did not show any protective effect against Aβ42-induced neurotoxicity in primary cortical neurons57 or a neuro-
blastoma cell line43. This is probably because 4G8 exhibits low-binding capacity to the turn structure of the toxic 
conformer36. One of the determinants of the clinical potency of AD therapies may be the specificity and reactivity 
to the toxic turn of Aβ42, not the affinity to senile plaques. This notion is supported by the fact that there was little 
correlation between the clinical severity of AD and the Aβ plaque burden in human patients58,59 and by the fact 
that there are cases in which patients have no clinical abnormalities despite plaque accumulation in the brain60–62.
Figure 4. The chronic administration of 24B3 did not alter the number or size of senile plaques. Representative 
images of immunohistochemical staining of senile plaque by 82E1 on the hippocampus of PS2Tg2576 treated 
with IgG (a), 82E1 (b), and 24B3 (c). The average number of senile plaques in the hippocampus (d). The average 
size of the senile plaques is shown in the graph (e). The numbers of mice sacrificed for staining in each group 
were as follows: PS2Tg2576 + IgG (n = 5), PS2Tg2576 + 82E1 (n = 6), and PS2Tg2576 + 24B3 (n = 6). *p < 0.05.
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In the chronic protocol, targeting the toxic conformer in the soluble fraction relieved cognitive dysfunction 
without affecting the number of senile plaques (Figs 3 and 4). Given that half-life of Aβ is almost half an hour63,64, 
there was a possibility that the acute administration of 24B3 is effective for cognitive recovery. In fact, in our 
investigation, only the single intravenous administration of 24B3 ameliorated the memory deficit in NOR test 
(Fig. 6). Surprisingly, this amelioration of memory impairment was not accompanied by a reduction in the levels 
of the toxic conformer (Fig. 6). In the in vitro experiment, 24B3 inhibited Aβ42-induced neurotoxicity (Fig. 1b 
and c). This probably occurred without a decrease in the levels of the toxic conformer in the medium, which is 
consistent with the results observed after the acute administration in vivo. These data imply that the expression 
of the acute beneficial effects of 24B3 does not necessarily require the reduction of the toxic conformer itself. 
Although the mechanism underlying the malignant effect of the toxic conformer remains to be elucidated, it is 
easy to assume that the toxic conformer binds to certain acceptor proteins, which convey the harmful signaling to 
induce synaptotoxicity and neurotoxicity, or inhibits the beneficial signaling for the cell survival or neural trans-
mission (Fig. 7). Given that the direct binding of 24B3 to the toxic conformer was confirmed by the IP methods 
(Supplementary Fig. 1), as reported previously43, the protective effect of 24B3 is assumed to be mediated by the 
Figure 5. The chronic administration of 24B3 reduced the levels of the toxic conformer of Aβ42. The levels 
of the toxic conformer of Aβ42 (a), total Aβ42 (b), and total Aβ40 (c) in the soluble fraction of the brain 
from PS2Tg2576 treated with IgG, 82E1 and 24B3. The levels of total Aβ42 (d), and total Aβ40 (e) in the 
insoluble fraction of brain from PS2Tg2576 treated with IgG, 82E1 and 24B3. The numbers of mice sacrificed 
for measurements in each group were as follows: PS2Tg2576 + IgG (n = 5), PS2Tg2576 + 82E1 (n = 6), and 
PS2Tg2576 + 24B3 (n = 6). *p < 0.05.
www.nature.com/scientificreports/
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prevention of binding between the toxic conformer and its acceptors, rather than by the clearance by immune 
cells (Fig. 7). The clinical trials of anti-Aβ immunotherapy revealed that clearance of the Aβ burden on micro-
vasculature can induce edema or micro-hemorrhage, so-called amyloid-related imaging abnormalities (ARIA)65, 
which is a common adverse effect of these types of immunotherapy. Even though aducanumab succeeded in 
deaccelerating the cognitive decline in mild to moderate AD patients, this antibody could not avoid these kinds 
of side effects derived from the potent capacity to clear the Aβ burden8. Aducanumab was reported to show 
enhanced microglial recruitment toward senile plaques8, while 24B3 did not show any additional activation of 
microglia (Supplementary Fig. 3). From this point of view, 24B3 may be associated with fewer adverse effects 
including ARIA.
Memory process is composed of multistage, such as acquisition, consolidation, retention, and retrieval; and 
memory is stored in the engram cells in hippocampus66. A recent study reported that AD mice exhibited impair-
ment in their retrieval of stored memory information before the plaque accumulation67, and that the activation 
of the memory engram cells improved this impairment67. In NOR test in the present study, each antibody was 
administered for three consecutive days after the acquisition phase. It is suggested (based on this experimental 
procedure) that 24B3 affects the retrieval stage of the memory process and that the toxic conformer is involved 
in the impairment of memory retrieval in AD model mice. Furthermore, we previously reported that the toxic 
conformer strongly inhibits long-term potentiation (LTP)35, which is a key step in memory acquisition68,69, and 
Figure 6. The single intravenous administration of 24B3 ameliorated memory impairment in Tg2576. 
(a) The protocol of the acute administration of 24B3. Female Tg2576 mice (16–18 months of age) received a 
single intravenous injection of control-IgG or 24B3 (20 mg/kg). The protocol of the novel object recognition 
test is detailed in Supplementary Fig. 4. (b) In trial 1, Wt mice and Tg2576 were injected with PBS. Wt mice 
exhibited a preference for the novel object; Tg2576 showed no preference. (c) In trial 2, Tg2576 treated with IgG 
exhibited no preference, while Tg2576 treated with 24B3 preferred the novel object. (d–f) The levels of the toxic 
conformer of Aβ42 (d), total Aβ42 (e), and total Aβ40 (f) in the soluble brain fraction of Tg2576 treated with 
IgG and 24B3. ***p < 0.001, *p < 0.05.
www.nature.com/scientificreports/
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which is disturbed in AD70. Taken together with this evidence, it is suggested that the toxic conformer of Aβ42 
plays several crucial roles in the memory impairment.
The present study put the toxic conformer forward for the promising therapeutic strategy for AD. In AD mice, 
24B3 showed sufficient specificity and affinity to the toxic conformer to ameliorate the cognitive impairment. 
In the case of AD patients, however, the therapeutic antibodies might require higher specificity and affinity. The 
clinical potency of 24B3 should be evaluated, and efforts are expected to be made to develop antibodies with 
high selectivity and affinity to the toxic conformer. In addition to immunotherapy, there are other approaches 
that can target the toxic conformer. The antagonism of the acceptors of the toxic conformer and the structural 
destabilization of the conformer are also appealing strategies. The elucidation of the mechanism underlying the 
development of cognitive impairment and neurotoxicity mediated by the toxic conformer is the next task to facil-
itate further drug development. The neutralization of the toxic conformer could lead to effective AD therapies 
with fewer adverse effects.
Methods
AD model mice. Tg2576 were purchased from Taconic Laboratories. PS2Tg2576 were developed by cross-
breeding with Tg2576 and human mutant PS2 (N141I) transgenic mice, which is previously generated as pre-
viously described49. Tg2576, PS2Tg2576 and littermate Wt mice were maintained in a 24 ± 1 °C room, with 
55% ± 10% relative humidity, under a 12 h light/dark cycle, with ad libitum access to food. All experimental 
procedures were performed in accordance with specified guidelines for the care and use of laboratory animals, 
and were approved by the Animal Care and Use Committee of Chiba University.
Antibody administration. 24B3, the monoclonal antibody against the toxic conformer, was obtained as 
previously described43,44. In brief, 24B3 was obtained by the immunization of mice with G9C, E22P-Aβ9–35, 
followed by repeated selection with the criteria of positivity to the turn-forming mutant Aβ42 and negativity 
to the turn-breaking mutant Aβ4243,44. 82E1 was developed as an antibody against the N-terminus of Aβ. As a 
control-IgG, we chose mouse monoclonal antibody against keyhole limpet hemocyanin (Immuno-Biological 
Laboratories). Both isotypes of the antibodies are IgG1.
Each antibody was diluted with PBS to adjust the concentration. The injection volume was 10 ml/kg of body 
weight. In the chronic protocol, each antibody was administered weekly to male and female PS2Tg2576 by intra-
peritoneal injection starting from 3 months of age for as long as 3 months at a dose of 10 mg/kg. In the acute 
protocol, each antibody was singly injected into the tail vein of female Tg2576 at 16–18 months of age at a dose of 
20 mg/kg. Wt mice recieved injection of PBS with the same frequency as antibodies.
Elevated plus maze (EPM) test. Spatial cognition was evaluated by the EPM test, as described previ-
ously71,72. The maze apparatus (Muromachi Kikai) consists of four arms (30 × 6 cm) and a central square 
(6 × 6 cm), all of which are located as high as 40 cm above the floor. Two arms are closed ones surrounded by 
vertical walls of 14 cm in height; the other two are open arms without walls. In the test, mice were placed alone 
Figure 7. A schematic illustration of the possible protective mechanism of 24B3. The toxic conformer of 
Aβ42 is assumed to directly bind to a certain acceptor via the toxic turn to trigger malignant signaling. 24B3 is 
assumed to mask the toxic turn to block binding to its acceptor, while 82E1 does not block binding. Thus, 24B3, 
but not 82E1, protects against cognitive impairment and neurotoxicity.
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on the central square and were allowed to explore freely for 10 min. The motions of the mice were automatically 
recorded with DV-Track Video Tracking System (Muromachi Kikai).
Nest construction test. The executive function was evaluated in nest construction test, the proto-
col of which was modified from a previous report73. Paper towel (Product number 37115, Nippon Paper) 
was used as the nest material. Ten pieces of paper (6 cm × 6 cm) were placed in the center of a clean cage 
(16.8 cm × 29.9 cm × 13.3 cm) and then mice were singly put in the cage. The nest building was assessed 4 days 
later according to the following criteria (Supplementary Fig. 2): score 0, no nesting or paper was scattered; 1, all 
paper was collected in a corner; score 2, all paper was collected in a corner and bitten or torn; 3, complete nesting 
was observed.
Novel object recognition (NOR) test. Long-term memory was evaluated by NOR test (Supplementary 
Fig. 4). Three experimental groups (Group I-III) were made from Wt and Tg2576. Before the test, the mice were 
placed into an open box (45 cm × 45 cm × 15 cm) for 10 min for 5 consecutive days to allow habituation. In this 
study, NOR test consisted of 2 trials. In trial 1, the mice were placed facing two similar objects (P and P’) for 
10 min for 3 successive days (acquisition phase); the next day, Group I-III received an intravenous injection of 
PBS. After 24 h, mice were placed facing object P and a novel object (object Q) for 10 min (test phase). In trial 2, 
the mice were placed facing two similar objects (R and R′) for 10 min for 3 successive days, and next day, Group 
I received an injection of PBS, while Groups II and III received IgG or 24B3. After 24 h, the mice were placed 
facing object R and a novel object (object S) for 10 min, and then sacrificed. In the test phase, the number of 
times the mice touched the objects with their nose was counted. The preference for the novel object was scored 
as the ratio of touches of the novel object to the total number of touches. It was confirmed that the mice had no 
significant preference for any of the objects. Any mice that showed a total touch count of <5 were excluded from 
the experiment.
Brain sampling. The mice were sacrificed at 48 h after the final administration of the antibody in the chronic 
protocol, and immediately after the behavioral experiment in the acute protocol. Under pentobarbital anesthesia 
(intraperitoneal injection), the mice were perfused with PBS to remove their blood and then their brains were 
collected. One hemisphere was frozen with liquid nitrogen for the biochemical assays; the other was soaked in 4% 
paraformaldehyde (Nacalai tesque) for fixation for immunohistochemical staining.
Aβ ELISA. Frozen brain hemispheres were homogenized in TBS with protease inhibitors (Complete mini, 
Roche), 0.7 µg/ml pepstatin A, and 1 mM phenylmethylsulphonyl fluoride. After the centrifugation (55,000 × g, 
30 min, 4 °C) of the homogenate, the resultant supernatant was collected as a soluble fraction. The pellet was 
suspended in 6 M guanidine-HCl (Wako) and centrifuged (55,000 × g, 30 min, 4 °C) to collect the supernatant as 
an insoluble fraction.
The concentrations of the toxic conformer of Aβ42, total Aβ42, total Aβ40 in the soluble and insoluble frac-
tions were measured by ELISA (Cat# 27709, 27719, and 27718, respectively, Immuno-Biological Laboratories) in 
accordance with the manufacturer’s instructions.
Immunohistochemistry. Five micrometer-thick coronal paraffin-embedded sections were prepared from 
fixed brain hemispheres. After deparaffinization and hydration, the slices were treated with formic acid (Nacalai 
Tesque) for 30 s for antigen activation. To inhibit the endogenous peroxidase, the brain sections were soaked 
in methanol with 0.1% H2O2 for 30 min. After washing with ice-cold PBS containing 0.02% Tween-20 (PBST), 
blocking was performed in blocking buffer, PBST with 10% goat serum (Sigma), for 30 min at room temperature. 
The first antibody, 82E1 (0.5 µg/ml) or 24B3 (20 µg/ml), diluted by blocking buffer was applied overnight at 4 °C. 
After washing with PBST, the second antibody, biotinylated mouse IgG (Vector Laboratories), diluted by blocking 
buffer was applied for 1 h at room temperature. The immunological signals were enhanced using an avidin biotin 
complex reaction kit (Vector Laboratories) including HRP-linked avidin. To visualize the signals, brain sections 
were treated with 3,3′-diaminobenzidine (Dojindo) solution in TBS with 0.1% H2O2. For reference, nuclei were 
stained with 4′,6-diamino-2-phenylindole (Dojindo). After dehydration and soaking in xylene, the brain sections 
were mounted with a coverslip and a reagent (Millipore).
MTT assay on rat primary neurons. The experimental procedures were approved by the Kyoto University 
Animal Experimentation Committee. Neuronal cultures were prepared from the cerebral cortices of fetal 
Wistar rats (Nihon SLC) at 17–19 days of gestation. The cultures were maintained in Neurobasal medium (Life 
Technologies) with 2% B-27 supplement (Life Technologies), 25 mM sodium glutamate, and 500 µM L-glutamine 
at 37 °C in a humidified atmosphere of 5% CO2. On the 5th day in vitro (DIV), the medium was replaced with 
sodium glutamate-free Neurobasal medium. Mature cultures (DIV8–12) were used for the experiments. In all 
experiments, B-27 supplement without antioxidants was used during the Aβ42 treatment.
Neurotoxicity was evaluated by MTT assay. Before treatment, Aβ42 was dissolved in PBS with 0.1% NH4OH, 
incubated for 30 min on ice, and then the Aβ42 solution was diluted 10 times with Neurobasal medium to adjust 
to the final concentration of 1 µM. After 96 h of treatment, the culture medium was replaced with medium con-
taining 0.5 mg/ml MTT (Nacalai Tesque), and the cells were incubated for 30 min at 37 °C, followed by replace-
ment with 2-propanol to lyse the cells. The absorbance at 595 nm was measured with a spectrometer (Microplate 
reader model 680, Bio-rad). The medium for vehicle treatment contained 0.01% NH4OH.
Statistical analyses. All data are presented as the mean ± s.e.m. The differences were analyzed with one-way 
ANOVA followed by Tukey’s test or unpaired Student’s t-test. P values < 0.05 were considered to indicate statis-
tical significance.
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Data Availability Statement. The datasets generated during the current study are available from the cor-
responding author on reasonable request.
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